Drugs / Tolevamer
Tolevamer
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT00382304 | Sep 2006 → Sep 2007 | Clostridium difficile colitis, acute diarrhea | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT00034294 | Feb 2002 → Jul 2003 | Clostridium difficile colitis, diarrheal disease, enterocolitis | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 33 trials · 2 missed | ||||||
| Phase 3 | NCT00466635 | Apr → Aug 2007 | Clostridium difficile colitis, diarrheal disease | Genzyme, a Sanofi Company | Terminated | No outcome recorded |
| Phase 3 | NCT00196794 | Apr 2005 → Aug 2007 | Clostridium difficile colitis, diarrheal disease | Genzyme, a Sanofi Company | Completed | Missed primary |
| Phase 3 | NCT00106509 | Mar 2005 → Feb 2007 | Clostridium difficile colitis | Genzyme, a Sanofi Company | Completed | Missed primary |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tolevamer | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00382304 ↗ |
| Known as | Exodif | “An Open-label Study to Assess the Safety, Efficacy and Absorption of Exodif™ (Tolevamer Potassium Sodium) Tablets in Patients With Clostridium Difficile-Associated Diarrhea” NCT00466635 ↗ |
| Known as | GT160-246 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00034294 ↗ |
| Known as | GT267-004 | “GT267-004 (tolevamer potassium sodium)” NCT00466635 ↗2“tolevamer potassium-sodium (GT267-004)” NCT00382304 ↗ “tolevamer potassium-sodium (GT267-004)” NCT00106509 ↗ |
| Known as | tolevamer potassium-sodium | “An Open-label Study to Assess the Safety, Efficacy and Absorption of Exodif™ (Tolevamer Potassium Sodium) Tablets in Patients With Clostridium Difficile-Associated Diarrhea” NCT00466635 ↗2“tolevamer potassium-sodium (GT267-004)” NCT00106509 ↗ “tolevamer potassium-sodium (GT267-004)” NCT00382304 ↗ |
| Modality | Other / unclassified | “tolevamer, a nonantibiotic, toxin-binding polymer” PMID 24799326 ↗ May 2014 |
| Route | Oral | “oral tolevamer 9 g (loading dose) followed by 3 g every 8 hours for 14 days” PMID 24799326 ↗ May 2014 |